Daniel Hiser, MD
Family Medicine · San Diego, CANPI 1376577973
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 130 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 20.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $597 and has fallen 93.8% since, to $37 in 2025.
Across 130 payments — averaging $20.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$537
- AbbVie$301
- Johnson & Johnson$205
- GSK$148
- Amgen$136
- Lilly USA, LLC$133
- plus $1K from 33 others
Across 1 payment — averaging $1023.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$1K
What the payments were for
- Food & beverage$2,614100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 30 | $537 |
| AbbVie(2 entities) | 15 | $301 |
| Johnson & Johnson | 8 | $205 |
| GSK | 6 | $148 |
| Amgen | 6 | $136 |
| Lilly USA, LLC | 7 | $133 |
| Pfizer | 7 | $115 |
| Amarin Pharma, Inc. | 4 | $87 |
| Seqirus USA Inc | 4 | $81 |
| Gilead | 3 | $70 |
| Hologic Sales And Service, LLC | 2 | $57 |
| Biohaven Pharmaceuticals, Inc. | 2 | $57 |
| Exact Sciences | 3 | $54 |
| Merck | 3 | $49 |
| Novartis | 2 | $39 |
| Otsuka America Pharmaceutical, Inc. | 2 | $39 |
| Novo Nordisk | 2 | $36 |
| Baxter Healthcare | 1 | $33 |
| Daiichi Sankyo Inc. | 2 | $31 |
| Medtronic | 1 | $30 |
| Cranial Technologies, Inc | 2 | $29 |
| Linus Health, Inc. | 1 | $25 |
| VBI Vaccine (delaware) Inc. | 1 | $25 |
| Philips North America LLC | 1 | $24 |
| Nevro Corp. | 1 | $24 |
| Shield Therapeutics Inc | 1 | $23 |
| Organon | 1 | $23 |
| Optos, Inc. | 1 | $21 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $18 |
| Lundbeck LLC | 1 | $18 |
| Coala Life Inc | 1 | $18 |
| Therapeuticsmd, Inc. | 1 | $17 |
| Vertiflex, Inc. | 1 | $17 |
| Evofem Biosciences, Inc. | 1 | $17 |
| Tactile Systems Technology Inc | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Exeltis, USA Inc. | 1 | $15 |
| Bayer | 1 | $14 |
How this compares
$2,614 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 39 | $43,817 |
| OzempicSemaglutide | 33 | $32,281 |
| XareltoRivaroxaban | 30 | $31,117 |
| JardianceEmpagliflozin | 24 | $25,839 |
| EliquisApixaban | 20 | $21,883 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $13,823 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 38 | $2,113 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $1,957 |
| Atorvastatin Calcium | 186 | $1,678 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 26 | $1,592 |
| Wixela InhubFluticasone Propion/Salmeterol | 11 | $1,439 |
| Levothyroxine Sodium | 107 | $1,361 |
| Valsartan | 86 | $1,037 |
| SynthroidLevothyroxine Sodium | 34 | $875 |
| Losartan Potassium | 82 | $853 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $537 | $43,81739 claims |
| Novo NordiskOzempic | $36 | $32,28133 claims |
| Johnson & JohnsonXarelto | $205 | $31,11730 claims |
| PfizerEliquis | $115 | $21,88320 claims |
| GSKTrelegy Ellipta | $148 | $13,82318 claims |
| AbbVieSynthroid | $301 | $87534 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.
Other family medicine in San Diego
- Bill McCarbergSan Diego$93K
- Sherly SoleimanEncino$1.2M
- Pamela KushnerLos Angeles$1.2M
- Sujata NarayanStanford$1.2M
- Jeffrey UngerChino$906K
- Alexander RivkinLos Angeles$866K
- Scott HowellLos Angeles$793K
- Derrick ButlerLos Angeles$692K
- Sandra CalmanMontara$589K
- Anthony JonesOakland$377K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.